Axcelis Technologies, Inc.

Good day, ladies and gentlemen, and welcome to the Axalis Technologies call to discuss the company's results for the fourth quarter and full year 2020. My name is Jerome, and I will be your coordinator for today. At this time, all participants are in a listen-only mode. We will be facilitating a question-and-answer session towards the end of the conference. If at any time during the call you require assistance, Please press star followed by zero, and a coordinator will be happy to assist you. As a reminder, this conference is being recorded for replay purposes. I would now like to turn the presentation over to your host for today's call, Mary Kuma, President and CEO of Axis Technologies. Please proceed, ma'am.

Thank you, Jerome. With me today is Kevin Brewer, Executive Vice President and CFO, and Doug Lawson, Executive Vice President of Corporate Marketing and Strategy. We are all participating in this call remotely, so I would like to apologize in advance for any technical difficulties. If you have not seen a copy of our press release issued last night, it is available on our website. Playback service will also be available on our website as described in our press release. Please note that comments made today about our expectations for future revenues, profits, and other results are forward-looking statements under the SEC Safe Harbor provision. These forward-looking statements are based on management's current expectations and are subject to the risks inherent in our business. These risks are described in detail in our Form 10-K Annual Report and other SEC filings, which we urge you to review. Our actual results may differ materially from our current expectations. We do not assume any obligation to update these forward-looking statements. Good morning and thank you for joining us. As a result of the strength of the overall electronics market and the growth of the Purion product family in 2020, Xcel has delivered its highest annual revenue in the last 15 years. To achieve this, our employees managed through many difficult logistical challenges brought on by the geopolitical environment and the continuing pandemic. I'd like to thank our employees for delivering these results while continuing to serve our customers and adhering to safety protocols. This challenging environment has continued into 2021, but despite this, we are planning for another year of growth at Excellus, The semiconductor industry is forecast to gain strength across all markets, and the Purion product family is poised for significant growth. Our fourth quarter financial performance was in line with our updated increased guidance. Revenue for the fourth quarter was $122.2 million, with earnings per share of 43 cents, gross margins of 43.4 percent, and a year-end cash balance of $204.2 million. EPS was favorably impacted by a previously unrecognized tax benefit of 11 cents per diluted share. For the full year 2020, revenue was $47.6 million with an EPS of $1.46. Our aftermarket business, or what we refer to as CS&I, once again contributed significantly to our revenue and gross margin. CS&I revenue was $58 million in Q4 and $181 million for the full year 2020. This strong performance was a result of high FAB utilization, the growing period on install base, and additional buying activity from one customer as a result of the current geopolitical situation. The growing mature process technology market continues to be an area of strength for Excellus, with 75% of Q4 shipments going to mature Foundry Logic customers. The other 25% went to memory customers, with NAND accounting for 15% and DRAM 10%. For the year, the mature process technology market accounted for 71% of shipments, with memory accounting for 29%. China continues to be a strong market for Excellus. The geographic mix of our system shipments in the fourth quarter was China 56%, the U.S. 20%, Korea 18%, and Taiwan 6%. For the year, our geographic split was China 54%, Korea 28%, the U.S. 5%, Europe 3%, Japan 2%, and Taiwan 8%. We expect the memory market will improve in 2021, but as a result of the continued growth in the mature markets and the strength of Excellus' product offerings in these segments, We expect that the mature markets will account for approximately 60 to 70 percent of our total shipments in 2021. During the fourth quarter, the U.S. government placed Chinese foundry customer SMIC on the entity list, meaning that licenses are required for all Excellus U.S. shipments to SMIC. We have applied for licenses and are prepared to ship these tools against customer requirements in the first quarter. As a result of the uncertainty related to these licenses, we are providing wider-than-usual guidance. For the first quarter, we expect revenue of between $118 and $138 million, gross margins of approximately 40 percent, operating profit of between $11 and $19 million, and earnings per share of between 22 and 42 cents. Continued growth of Purion products is the key to achieving our long-term business models. We shipped the first Purion 200 revenue tool to a second customer for use in power device manufacturing. The power device market is a critical market for Excellus, and targeted Purion products for silicon carbide, including the Purion H200, will play a key role in increasing our customer base and revenues in this segment. We currently have six period on evaluation tools in the field focused on supporting growth towards our $650 million business model. During the first quarter, we expect to close one of these evaluations and ship an additional new one, resulting in a balance of six evaluation systems in the field as we head into the second quarter. Before Kevin reviews the financials, I would like to summarize four key takeaways. First, The mature process technology market is very strong and growing, and Excellus is the ion implant market leader in this segment. Second, memory is expected to recover in 2021 and will be additive to our strong, mature process technology performance. Third, China will continue to be an important market for Excellus, driven by many customers, both domestic and multinational. And fourth, The Purion product family is extremely well positioned to support future growth and our $650 million business model. Now I'd like to turn it over to Kevin to discuss our financials and some operational details. Kevin?

Thank you, Mary, and good morning. Accel has delivered exceptional fourth quarter and full year 2020 financial performance thanks to the continued outstanding work of our employees and supply chain partners. Strong execution across the board and significant leverage in our business model delivered 140 percent increase in operating profit and revenue growth of 38 percent. During this ongoing pandemic, the health and well-being of our employees remains a top priority. We are doing our best to create a safe work environment for everyone at Excel. Pandemic-related protocols that were implemented during 2020 remain in place for 2021. Our pandemic response team will continue to closely monitor these actions and update as required. We remain focused on our target business model and expect 2021 to be another growth year for Accelvix. We will continue to invest in product, evaluation tools, and infrastructure needed to support our $650 million target model. Turning to fourth quarter and full year financial results, Q4 revenue finished at $122.2 million and above our updated guidance compared to $110.4 million in Q3. Q4 system sales was $64.2 million compared to $70.2 million in Q3. Q4 CS&I revenue finished at $58 million compared to $40.2 million in Q3. The unusually high CS&I revenue in Q4 was driven by fabulization, a growing period on install base, and significant buying in the quarter by one of our customers. We expect Q1 CS9 revenue approximately $42 million and recommend modeling at this quarterly level for 2021. Full year 2020 revenue was $474.6 million compared to $343 million in 2019. an increase of 38 percent. The system's revenue was $293.6 million compared to $202.6 million in 2019, an increase of 45 percent. The F&I revenue was $181 million compared to $140.4 million in 2019, an increase of 29 percent. Q4 sales to our top 10 customers accounted for 81.5% of our total sales, compared to 76% in Q3. Three customers were at 10% or above in Q4, the same as Q3. For the full year, 74% of revenue came from our top 10 customers, with two at 10% or above. Q4 system bookings were $131.5 million compared to $26.4 million in Q3, with a Q4 book-to-bill ratio of 1.98 versus 0.37 in Q3. Backlogging Q4 including deferred revenue finished at $93.2 million compared to $45.1 million in Q3. Q4 combined SG&A and R&D spending was $38.9 million with 31.8 percent of revenue compared to 34.3 million, or 31 percent, in Q3. Q4 combined SG&A and R&D spending was higher than forecast, primarily driven by variable compensation expense. SG&A in the quarter was $22.6 million, with R&D at $15.3 million. In Q1, we expect SG&A and R&D spending to be approximately $36 million, and run at this level through the remainder of 2021. Q4 gross margin was 43.4 percent and above our updated guidance. Q4 gross margin was driven by higher-than-forecast CS&I revenue and continued cost-out activity. Full-year gross margin was 41.8 percent compared to 42 percent in 2019. We're guiding Q1 gross margin of approximately 40 percent driven by a less favorable mix of products and enclosure of an evaluation system. Gross margins will fluctuate quarter to quarter based on product and customer mix, the number of evaluation tools closed, and a percent of revenue contribution for our creative CS&I business. We've made solid progress on gross margin improvements with cost of initiative, new care and product extension, and growth in our CS&I business. Our target models reflect additional gross margin improvement from incremental volume, higher sales of serum product extensions, and continued savings from lean manufacturing and value engineering. Operating profit in Q4 finished at $14.1 million, compared to $13.9 million in Q3. Full-year operating profit was $68 million, an increase of 140%, compared to $24.2 million in 2019. We had a guiding Q1 operating profit of between $11 and $19 million. Q4 net income was $14.7 million, or 43 cents per share, compared to 10.8, or 32 cents per share in Q3. Net income and EPS were favorably impacted by a previously unrecognized tax benefit of 11 cents per diluted share. Full unit income was $50 million, or $1.46 per share, compared to $17 million, or 50 cents per share, in 2019, resulting in a greater than 190% year-over-year increase. We're guiding Q1 earnings per share between 22 and 42 cents. Our Q1 guidance reflects our current assessment of the potential impact on a business from the coronavirus and the export control situation with a specific customer in China, which we will continue to closely monitor. Q4 cash finished at $204.2 million compared to $212.7 million in Q3. We announced a $100 million share repurchase program for 2021. Q4 receivables were $86.9 million compared to $45.2 million in Q3. Q4 inventory ended at $161 million compared to $159.7 million in Q3. Q4 inventory terms excluding evaluation tools finished at 2.0 compared to 1.8 in Q3. Q4 accounts payable were $24 million compared to $24.3 million in Q3. We finished 2020 with strong momentum and are excited about the prospects of recovery in the memory and automotive market. We continue to make the necessary investments in our product and the infrastructure needed for our $650 million target model. Our customers continue to have high expectations for our theorem product, which we intend to achieve. Thank you, and I'll now turn the call back to Mary for closing comments.

Thank you, Kevin. We are pleased with our fourth quarter financial performance as well as our exceptional overall performance in 2020 and are looking forward to another year of growth in 2021. Excellus has a competitive Purion product line, a broad and diverse customer base, a strong balance sheet, and a dedicated team of employees. These are the strengths that will continue to drive our growth toward our $650 million model and ultimately to a market leadership position in ion implantation. With that, I'd like to open it up for questions. Jerome?

Ladies and gentlemen, if you wish to ask a question, please press star followed by one on your touchstone telephone. If your question has been answered or you wish to withdraw your question, press the pound key. Please press star once again. Your first question comes from the line of Patrick Hall with the default

Thank you very much and congrats on the really nice finish to the year and the Outlook for 21. Maren, maybe first off in terms of the market environment. You're talking about a memory recovery in 21. Compared to three months ago, do you see the magnitude of that memory recovery being quote, greater than it was three months ago. And I guess, how does that potentially impact, you know, from their standpoint, the way for SNR to build out, as well as how many tools you may be shipping to the memory market in 21?

Okay. So, Patrick, you know, we've been saying now for quite a while that we expect a recovery in memory in 2021. I think if you take a look back, if you remember, in Q3, we actually shipped no systems to any memory customers. In Q4, that had increased to 25%. And we're actually saying that we expect memory to account for 30% to 40% of our systems revenue in 2021. And that's in comparison and up from 29%, which is where we ended for full year 2020. We are, you know, starting to see some signs of the memory recovery, and we expect it to continue throughout the remainder of the year. Doug, I don't know if you have anything you want to add to that.

I'm sure. Thanks, Mary. Patrick, the recovery that we're seeing, you know, this past quarter is, you know, split 15 and 10 percent for DRAM and NAND, and we expect we're seeing activity on both fronts, both NAND and DRAM. And so as we've been saying about this particular memory recovery, we see it as more of a longer-term, you know, couple-year kind of recovery versus what we saw back in 17 and 18 where it was very steep. There will ultimately be more, you know, area under the curve in terms of growth as a result. And, you know, we're poised to do well there with our position. The percentages of memory versus, you know, versus mature in our projections are primarily due to the fact that the mature markets are just so active right now. And that's, you know, become a much bigger piece of our business compared to what it was back in the 17-18 timeframe.

Great. That's helpful. And maybe as my follow-up question for Kevin in terms of your work in capital management, AR obviously was a little bit up, which may highlight some of the linearity, but, you know, you're also building some inventory. Have you run into any supply constraints on your end as you're preparing for, you know, a higher level of shipment this year? Any supply constraints or issues on that front in procuring parts?

Yeah, thanks, Pat. That's a good question. So, you know, I would say the supply chain – Constraints are what they've been for most of 2020, you know, with the pandemic. Things were tight. We've continued to drive inventory probably a little ahead of where we needed to be so that we're not, you know, waiting for long lead material. And, you know, as things kind of tightened up in different spots in 2020, we were able to move things around a little bit. We do have, in some cases, multiple suppliers. So it's about the same now. I think the pandemic-related issues are improving. But as you point out, the industry is ramping, so there's additional pressure coming for a different reason now. But all in all, I would say, you know, it's about what we had to deal with last year, so I don't expect any issues with keeping up with what we need to do this year ramping. Great. Thank you very much. Yep. Thanks, Patrick.

Your next question comes from the line of Craig Ellis with B Reilly Securities. You know, ask your question.

Thanks for taking the questions and congratulations on a real strong 2020 and finish to the year team. So I just wanted to start with a near-term question. It's clear that the company believes that CS&I will move backwards to that 42 million level, but within the memory and mature foundry business, can you just characterize some of the gives and takes for the first quarter and help us understand how DRAM versus NAND might be performing to start the year?

Okay. So, oh, go ahead. Doug, you can take it if you'd like.

Okay. Sorry about that. So, Craig, you know, we're seeing activity on both fronts. And as you know, we're more dependent on wafer start additions, and so we are seeing activity from both sides. It was split relatively evenly in the fourth quarter. As we look at the first quarter, we're seeing activity in both fronts. So it looks good. From a mature standpoint, the mature markets are very active. have been, you know, throughout 2020 and continue, you know, and we don't see that slowing down in 2021, so.

That's helpful.

Yeah, Craig, if you want.

Go ahead, Mary.

No, I was just going to give a little bit more color on the mature markets. So, you know, last year, image sensor and the general mature foundry business was very strong, and it continues to be into 2021. Automotive showed weakness, but we do see it recovering, and that's going to be positive for the power device market, which is going to be positive for Excellus. And then, as Doug said, we're seeing activity on both sides of memory. So we're getting to the point where we see most of our markets and market segments beginning to hit on full cylinders.

That's great. And then longer term, the company commented on on memory being 30 to 40 percent of systems. Can you just characterize the demand visibility that you have through calendar 21 in different parts of mature foundry and with the RAM and NAND specifically so we can get a sense of how far out order visibility extends now?

Yeah, I mean, I think we have very good visibility into the first half of the year and things are starting to become more clear moving into the second half of the year. But we are seeing changes in terms of customer timing, both pull-ins and some delays in some cases, not really because of the market. I think what I would say, I would characterize it mostly as some slight delays in fab readiness So we expect, that's normal for us, though. I don't think we're seeing anything that's necessarily, you know, out of the ordinary at this point in time. So as I said, you know, first half, visibility good. Second half, starting to improve. And I think customers do realize that given the ongoing challenges, you know, with the pandemic and in some cases the geopolitical situation, they may need to lock in on their forecast and notify suppliers maybe a little bit sooner than they normally would just because they want to make sure they get in the queue for their systems given some of the lead times that are out there right now. Kevin just commented that Things seem to be manageable at this point in time, but, you know, you add a ramp on top of a pandemic and, you know, you can get some issues at some point moving forward. So customers are aware of that.

Absolutely. And then one final one before I hop back in the queue. It's a multi-parter and more in the political realm. The first part of it would be, can you provide us any color on the optics that you have into the the license-granting process, and then on the other side of that, I think it was within the last two days that a number of the very large U.S. chip companies were speaking to the new administration and really expressing the need for a lot more federal government help building out the U.S. chip supply industry. If something were to happen in that regard, what would it mean for Excellus?

Well, you know, we're monitoring all the geopolitical, the situation and the issues, obviously, on an ongoing basis. And so, you know, we've got our legal counsel watching it carefully. We're working with outside trade attorneys. We're very involved with SEMI, you know, our industry trade group, to make sure that our voice is heard as well as to better understand the situation. Obviously, investment in semiconductor companies fabs would be a positive thing. And in the U.S., we would love that. We think that that would be a real upside for the U.S. government, the country, and for Excellus. In terms of some of the other geopolitical issues, there's really not a lot to say about what's going on with the licenses. I think that's maybe what you were poking at a little bit, Craig. You know, we've applied for the licenses. We are prepared to ship systems and parts against customer requirements as soon as we receive the licenses. And, you know, we just haven't heard anything back yet. As far as we understand, we don't believe that anything significant has changed based on, you know, the change in administration. But again, we're all basically just waiting.

That's helpful. Thanks very much, Mary.

Your next question comes from the line of Christian Schropp with Craig Kalen. He's going to ask a question.

Hey, guys. This is Tyler on behalf of Christian. Thanks for letting us ask a couple questions. First question, I think you alluded to it, but maybe a little more color. What's your expectation as far as the timing of the memory recovery through the year? Are you expecting kind of a step up here in Q1 or just a gradual improvement through the year? Any color on timing would be great.

I don't think we necessarily have, you know, enough visibility. I mean, I just alluded to the fact that there's visibility in Q1 that leads us to believe that there is a memory, and we have visibility into the first half, I'm sorry, and we, you know, which leads us to believe that a memory, a memory recovery will occur in 2021. But we just don't have a view at this point in time and we're not really going to forecast that in terms of putting numbers around it. So as I mentioned before, we're seeing an improvement in the percentage of systems that we're shipping out to memory and we do expect that as a percent over the course of the year to increase versus last year, so 30% to 40% versus 29%. But, you know, in terms of the timing, we're just going to continue to watch, talk to our customers and watch the trends in the market.

Understood. That's very helpful. Second question then, I believe previously your comments were that at some point in 2021 you expected to reach a a run rate of your $550 million annual model. So I guess, you know, given where Q1 is guided and expectations for an improving memory market and an improving automotive market, you know, I'm wondering if it's reasonable to think that, you know, the full year 21 could end up being, you know, close to or approach that $550 million annual target.

Yeah, Tyler, it's Kevin. Yeah, so obviously it's in our line of sight right now with the guide we just gave. So you're right. We had kind of been saying at some point we had to run rate in 2021 and then it was a 2022 event. You know, we're not providing full-year guidance at this point, but, you know, as you point out and as I just said, it's in our line of sight at this point. And, you know, the 650 model, as we continue to say is a couple years after the 550. But obviously, we're setting up well, coming out of the gate to do one.

Sounds great. Very helpful. That's all from me, guys. Thanks.

Thank you. Your next question comes from the line of Tom DeFalle with DA Davidson. You may now ask your question.

Yeah, good morning. Thanks for the question. Mary, you said that you expect to close one of your eval tools during the quarter, and I'm wondering, what is your thought as far as the process of starting to ramp up production tools based off of the eval over the next few quarters?

I think the prospects are actually very good. I will actually say that for this evaluation, We have already shipped some repeat orders to that customer prior to the evaluation closing, so we definitely have been selected as PTOR for the specific application. We've shipped some repeat tools, and we expect to ship some additional tools moving forward.

Great. And then, Kevin, when you look at the margin profile, how big an impact does both the closing of the eval tool have on the margin? in the quarter, and then when you look at the top and the bottom of your guidance range, what is the impact of the margins there?

Yeah, so, I mean, evals always have a negative effect. Some evals, you know, have higher costs than others, so that certainly moves it, and a number of evals. You know, I think what's going on in Q1 is, you know, we've got the evals going out. We've also got a higher mix of high-current fuels going out, which which overall is good for the company because that's a large market and that's, you know, one of the areas you want to continue growing as high current. But, you know, maybe I could help you a little bit more. If I look at the full year right now, Tom, you know, I'm seeing full year gross margin in 2021 similar to what they were in 2020. And that includes a number of evals closing out. As Mary said, we've got one closing on November going out, which is six. And I think as you recall, you know, typically we would have two or three. So we've been saying for the last couple of quarters there's a high number of evals and more going. So, you know, those are sitting on the margins. And the other thing, you know, we're going to see a lot of growth this year coming from systems versus, you know, CS&I, right? So as the systems grow next year in the three to CS&I, um you know that can pressure things a little bit but the good news is you know with all that in their growth and systems all these evals i i at this point you know expect gross margins for a year to finish similar to last year and our target model is 42 to 43 on 550 so we're we're you know we're just off of that a tiny bit and if you look at you know try to do the math and figure when we get there and think about cost initiatives, maybe we get there a little bit sooner than we thought, you know, some of these initiatives still have to kick in. So I, from a gross margin point of view, I feel really good where we are right now and expect this year to, you know, to continue to drive costs out and get the value into there and more product extensions. And those, those are all things we need to get to our model. And then, you know, the 650 model is, margins are up to 44 to 45, and that's a couple of years later. So, again, we're in good shape.

Great. That's very helpful. Thanks for the questions. Yes, thank you.

Your next question comes from the line of Mark Miller with The Benchmark. Can we now ask your question?

Thank you for the question. Congrats on your progress. Were there any shares repurchased last quarter?

There were not, Mark. So the program that was in place last year was suspended in Q1. They did not put that back in place. And then the board approved the new program for this year, $100 million. And as a reminder, the prior program was $50 million, and we had spent about $25 million in purchasing shares prior to putting that on hold.

You indicated a recovery in the auto sector. I'm just wondering, is that starting to accelerate? Because there's been a lot of talk about chip shortages facing the auto manufacturers, and I'm just wondering if that's really starting to accelerate significantly.

Mark, can you repeat the question? I heard the chip shortages, but I wasn't sure what the front end was.

There's been reports the auto manufacturers are facing chip shortages. I'm just wondering, you said there was recovery going on in the auto. Is that starting to really accelerate as the quarter went on?

We started seeing it pick up in the last quarter. It's, you know, we see it in a few different areas. We see it, you know, in the power device area, which started to strengthen last quarter. And we see that continuing to grow throughout the year. The image sensor market is a big piece of the automotive world these days. And that's been strong. And it's hard for us to tell exactly what's going to automotive versus phones and other image sensor applications. And then the general foundry which, you know, general mature foundry which is what's really all in the press these days. where everybody's talking about 20 cent parts keeping lines down. That whole foundry, mature foundry market has been strong. Utilizations in that segment have been very high. And so that's been a big piece of our business over the course of 2020 as people bought all the consumer electronics and PCs and so forth. And, you know, that will continue now that you start layering automotive on top of it.

Thank you.

Your next question comes from the line of Corinne Bolton with Needham & Company. You may now ask your question.

Congratulations on the nice results. I just wanted to ask, maybe I missed it, but did you say which of the six eval tools had been accepted for revenue recognition or will be accepted for REBREC in the March quarter?

No, we didn't say which one would be accepted in Q1, and we didn't talk yet about the new one that will be going out in the quarter either. So we'll give more color on that as we progress through the quarter and into next quarter.

I think it was Tom's question that you've already received repeat orders for that eval tool that was closed.

We have. I guess the only additional color I'll give around it is for an image sensor application, and we'll just leave it at that.

Thank you, Mary. The second question I had is from the CS&I strength in the fourth quarter. It looks like perhaps you're not subject to export controls for that part of the business. Just wondering if that's the right read. And given the very strong, you know, level at 58 million, is there a risk that, you know, that customer doesn't purchase for some time and And CSNI revenue could actually come in below $42 million at some point as that customer digests inventory of spares.

Yeah, I'm not worried about that. I think that the customer who did a lot of buying is also running at a very high utilization rate. And we have shipped a number of tools there, and I think they're probably putting more parts of the meat in the shelf, but I think they're going to continue to buy anyway. As the business grows around this, we had strength across the board. I spiked out the one customer, but there's continued strength across the board. I think the $42 million number that we put out there to model to is the right number to be using. I don't see any downside risk to that.

Just lastly, Kevin, You know, for the $100 million share repurchase program, can you give us any sense, you know, is that going to be under 10b-5-1? Will you be sort of in the market on a consistent basis? Are you going to try to be opportunistic? Any sort of thoughts on how that $100 million buyback is executed this year?

Yeah, Quinn. So wait. We'll use the 10D51, which is similar to what we did on the program last year that we were executing under. And, you know, beyond that, whether it will be opportunistic or not, I mean, it'll be a board-approved grid that we buy to. And, you know, I think, you know, the board and management, you know, realize that, you know, we should be returning cash to shareholders through, through some type of program which we agreed is a shared purchase. So, you know, I'm not going to say how much we're going to spend because, right, I mean, we put it out there. We could spend it all or a good portion of it. But I guess what I'll leave you is we realize that we need to be utilizing this program. So, again, that's – No, I know you're limited.

Yeah. Yeah, no, I know you can't give us too much on – on timing or amount, but, you know, thanks for the color you did provide. And that's it for me. I'll go back in the queue. Thank you.

Yeah, thanks.

All right. We have no question at this time. Again, to ask a question, please press R, then the number one on your telephone keypad. This concludes the Q&A portion of the call. I will now turn the call back over to Mary Puma, who will make a few closing remarks.

I'd like to thank everyone for joining us today, and we hope to talk with you virtually at upcoming investor events. We will be participating in Susquehanna Financial Group's 10th Annual Technology Conference in March. We expect to conduct several virtual NDRs during the quarter as well. We thank you for your continued support and please stay healthy.

This concludes the presentation. Thank you for your participation in today's conference. You may now disconnect. Good day, everyone.